Edodekin alfa Completed Phase 2 Trials for Extranodal marginal zone B-cell lymphoma (MALT type) / Splenic Marginal Zone Lymphoma / Nodal marginal zone B-cell lymphomas / Recurrent Grade 1 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / B-cell Small Lymphocytic Lymphoma Recurrent / Recurrent Grade 2 Follicular Lymphoma Treatment

Indications	Status	Purpose	Phase
DBCOND0006810 (Extranodal marginal zone B-cell lymphoma (MALT type)) DBCOND0028622 (Splenic Marginal Zone Lymphoma) DBCOND0026817 (Nodal marginal zone B-cell lymphomas) DBCOND0028501 (Recurrent Grade 1 Follicular Lymphoma) DBCOND0028615 (Recurrent Mantle Cell Lymphoma) DBCOND0051780 (B-cell Small Lymphocytic Lymphoma Recurrent) DBCOND0028502 (Recurrent Grade 2 Follicular Lymphoma)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00026182	Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Edodekin alfa (DB15631) Natural Killer Cell (DB15721) Rituximab (DB00073)